Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128 · cited 1×

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

Herman, S. E. M., Gordon, A. L., Hertlein, E., Ramanunni, A., Zhang, X., Jaglowski, S., Flynn, J., Jones, J., Blum, K. A., Buggy, J. J., et al. (2011) · Blood · doi:10.1182/blood-2011-01-328484 · Cited by 807

Long-term Outcome of 525 Patients With Mycosis Fungoides and Sézary Syndrome

Kim, Y. H., Liu, H. L., Mraz‐Gernhard, S., Varghese, A., & Hoppe, R. T. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.7.857 · Cited by 652

Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug

Ramsay, A. G., Johnson, A. J., Lee, A. M., Görgün, G., Dieu, R. L., Blum, W. G., Byrd, J. C., & Gribben, J. G. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35017 · Cited by 619

T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993)

Marks, D. I., Paietta, E. M., Moorman, A. V., Richards, S. M., Buck, G. A. N., Dewald, G. W., Ferrando, A. A., Fielding, A. K., Goldstone, A. H., Ketterling, R. P., et al. (2009) · Blood · doi:10.1182/blood-2009-08-231217 · Cited by 420

The B-cell receptor signaling pathway as a therapeutic target in CLL

Woyach, J. A., Johnson, A. J., & Byrd, J. C. (2012) · Blood · doi:10.1182/blood-2012-02-362624 · Cited by 412

Requirement for Tec Kinases Rlk and Itk in T Cell Receptor Signaling and Immunity

Schaeffer, E. M., Debnath, J., Yap, G. S., McVicar, D. W., Liao, X. C., Littman, D. R., Sher, A., VARMUS, H. E., Lenardo, M. J., & Schwartzberg, P. L. (1999) · Science · doi:10.1126/science.284.5414.638 · Cited by 398

TEC FAMILY KINASES IN T LYMPHOCYTE DEVELOPMENT AND FUNCTION

Berg, L. J., Finkelstein, L. D., Lucas, J. A., & Schwartzberg, P. L. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104743 · Cited by 341

T Cell Receptor–initiated Calcium Release Is Uncoupled from Capacitative Calcium Entry in Itk-deficient T Cells

Liu, K., Bunnell, S. C., Gurniak, C. B., & Berg, L. J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.10.1721 · Cited by 337

Immunological effects of conventional chemotherapy and targeted anticancer agents

Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530

Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib

Woyach, J. A., Furman, R. R., Liu, T.-M., Ozer, H. G., Zapatka, M., Ruppert, A. S., Xue, L., Li, D. H.-H., Steggerda, S. M., Versele, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400029 · Cited by 1,275

Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy

Morris, E. C., Neelapu, S. S., Giavridis, T., & Sadelain, M. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00547-6 · Cited by 1,187

Prospects for combining targeted and conventional cancer therapy with immunotherapy

Gotwals, P. J., Cameron, S. B., Cipolletta, D., Cremasco, V., Crystal, A., Hewes, B., Mueller, B., Quaratino, S., Sabatos-Peyton, C. A., Petruzzelli, L., et al. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.17 · Cited by 968

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

Byrd, J. C., Harrington, B. K., O'Brien, S. M., Jones, J. A., Schuh, A., Devereux, S., Chaves, J. M., Wierda, W. G., Awan, F. T., Brown, J. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509981 · Cited by 916

Role of Bruton’s tyrosine kinase in B cells and malignancies

Pal Singh, S., Dammeijer, F., & Hendriks, R. W. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0779-z · Cited by 726

Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

Byrd, J. C., Furman, R. R., Coutre, S. E., Burger, J. A., Blum, K. A., Coleman, M., Wierda, W. G., Jones, J. A., Zhao, W., Heerema, N. A., et al. (2015) · Blood · doi:10.1182/blood-2014-10-606038 · Cited by 674

Combination strategies to maximize the benefits of cancer immunotherapy

Zhu, S., Zhang, T., Zheng, L., Liu, H., Song, W., Liu, D., Li, Z., & Pan, C.-X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01164-5 · Cited by 654

Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia

Maddocks, K. J., Ruppert, A. S., Lozanski, G., Heerema, N. A., Zhao, W., Abruzzo, L., Lozanski, A., Davis, M., Gordon, A., Smith, L. L., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2014.218 · Cited by 584

Targeting Bruton's tyrosine kinase in B cell malignancies

Hendriks, R. W., Yuvaraj, S., & Kil, L. P. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3702 · Cited by 580

Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management

Sunder, S. S., Sharma, U. C., & Pokharel, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01469-6 · Cited by 572

Ibrutinib for chronic graft-versus-host disease after failure of prior therapy

Miklos, D. B., Cutler, C. S., Arora, M., Waller, E. K., Jagasia, M., Pusic, I., Flowers, M. E. D., Logan, A. C., Nakamura, R., Blazar, B. R., et al. (2017) · Blood · doi:10.1182/blood-2017-07-793786 · Cited by 520

Myeloid immunosuppression and immune checkpoints in the tumor microenvironment

Nakamura, K., & Smyth, M. J. (2019) · Cellular and Molecular Immunology · doi:10.1038/s41423-019-0306-1 · Cited by 530

Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma

Lionakis, M. S., Dunleavy, K. M., Roschewski, M. J., Widemann, B. C., Butman, J. A., Schmitz, R., Yang, Y., Cole, D. E., Melani, C. J., Higham, C. S., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.012 · Cited by 518

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

Fraietta, J. A., Beckwith, K. A., Patel, P. R., Ruella, M., Zheng, Z., Barrett, D. M., Lacey, S. F., Melenhorst, J. J., McGettigan, S. E., Cook, D. R., et al. (2016) · Blood · doi:10.1182/blood-2015-11-679134 · Cited by 474

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

O'Brien, S. M., Furman, R. R., Coutre, S. E., Sharman, J. P., Burger, J. A., Blum, K. A., Grant, B., Richards, D., Coleman, M., Wierda, W. G., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70513-8 · Cited by 469

PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas

Goodman, A. M., Patel, S. P., & Kurzrock, R. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.168 · Cited by 459

Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK

Sagiv-Barfi, I., Kohrt, H. E. K., Czerwinski, D. K., Ng, P. P., Chang, B. Y., & Levy, R. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1500712112 · Cited by 445

Targeting B cell receptor signalling in cancer: preclinical and clinical advances

Burger, J. A., & Wiestner, A. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.121 · Cited by 431

Prolonged and tunable residence time using reversible covalent kinase inhibitors

Bradshaw, J. M., McFarland, J. M., Paavilainen, V. O., Bisconte, A. R., Tam, D., Phan, V. T., Romanov, S., Finkle, D., Shu, J., Patel, V. P., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1817 · Cited by 437

Targeting the C481S ibrutinib-resistance mutation in Bruton’s tyrosine kinase using PROTAC-mediated degradation

Buhimschi, A. D., Armstrong, H. A., Toure, M., Jaime-Figueroa, S., Chen, T. L., Lehman, A. M., Woyach, J. A., Johnson, A. J., Byrd, J. C., & Crews, C. M. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00391 · Cited by 394

Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile

Barf, T. A., Covey, T. M., Izumi, R. E., van de Kar, B., Gulrajani, M., van Lith, B., Hoek, M. E.-V., de Zwart, E., Mittag, D., Demont, D., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.242909 · Cited by 399

Ibrutinib treatment improves T cell number and function in CLL patients

Long, M., Beckwith, K. A., Do, P., Mundy-Bosse, B. L., Gordon, A. L., Lehman, A. M., Maddocks, K. J., Cheney, C. M., Jones, J. A., Flynn, J. M., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89756 · Cited by 387

The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?

Shin, D. S., & Ribas, A. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.01.006 · Cited by 351

Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study

Wang, M. L., Munoz, J. L., Goy, A. H., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H. E., Jaglowski, S. M., Flinn, I. W., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02370 · Cited by 337

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

Burger, J. A., Keating, M. J., Wierda, W. G., Hartmann, E., Hoellenriegel, J., Rosin, N. Y., de Weerdt, I., Jeyakumar, G., Ferrajoli, A., Cárdenas-Turanzas, M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70335-3 · Cited by 337

Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma

Noy, A., de Vos, S., Thiéblemont, C., Martin, P., Flowers, C. R., Morschhauser, F., Collins, G. P., Ma, S., Coleman, M., Peles, S., et al. (2017) · Blood · doi:10.1182/blood-2016-10-747345 · Cited by 303

Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies

Siegler, E. L., & Kenderian, S. S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01973 · Cited by 295

Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects

Estupiñan, H. Y., Berglöf, A., Zain, R., & Smith, C. I. E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.630942 · Cited by 274

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

Walter, H. S., Rule, S. A., Dyer, M. J. S., Karlin, L., Jones, C. H., Cazin, B., Quittet, P., Shah, N., Hutchinson, C. V., Honda, H., et al. (2015) · Blood · doi:10.1182/blood-2015-08-664086 · Cited by 274

Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL

Herman, S. E. M., Mustafa, R. Z., Gyamfi, J., Pittaluga, S., Chang, S., Chang, B. Y., Farooqui, M. Z. H., & Wiestner, A. U. (2014) · Blood · doi:10.1182/blood-2014-02-548610 · Cited by 250

Ibrutinib antagonizes rituximab-dependent NK cell–mediated cytotoxicity

Kohrt, H. E. K., Sagiv-Barfi, I., Rafiq, S., Herman, S. E. M., Butchar, J. P., Cheney, C. M., Zhang, X., Buggy, J. J., Muthusamy, N., Levy, R., et al. (2014) · Blood · doi:10.1182/blood-2014-01-547869 · Cited by 218

Disruption of in vivo Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study

Niemann, C. U., Herman, S. E. M., Marić, I., Gómez‐Rodríguez, J., Biancotto, A., Chang, B. Y., Martyr, S. E., Stetler‐Stevenson, M., Yuan, C. M., Calvo, K. R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1965 · Cited by 206

Ibrutinib treatment ameliorates murine chronic graft-versus-host disease

Dubovsky, J. A., Flynn, R. P., Du, J., Harrington, B. K., Zhong, Y., Kaffenberger, B. H., Yang, C. S., Towns, W. H., Lehman, A., Johnson, A. J., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75328 · Cited by 205

B‐cell receptor signalling and its crosstalk with other pathways in normal and malignant cells

Šeda, V., & Mráz, M. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12427 · Cited by 218

Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?

Dreger, P., Schetelig, J., Andersen, N. S., Corradini, P., van Gelder, M., Gribben, J. G., Kimby, E. K., Michallet, M., Moreno, C., Stilgenbauer, S., et al. (2014) · Blood · doi:10.1182/blood-2014-07-586826 · Cited by 203

Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study

Younes, A., Brody, J., Carpio, C. D. C., López‐Guillermo, A., Ben‐Yehuda, D., Ferhanoğlu, B., Nagler, A., Özcan, M., Avivi, I. M., Bosch, F., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30217-5 · Cited by 197

Ibrutinib: A First in Class Covalent Inhibitor of Bruton's Tyrosine Kinase

Davids, M. S., & Brown, J. R. (2014) · Future Oncology · doi:10.2217/fon.14.51 · Cited by 200

Myeloid-derived suppressor cells express Bruton's tyrosine kinase and can be depleted in tumor-bearing hosts by ibrutinib treatment

Stiff, A., Trikha, P., Wesolowski, R., Kendra, K., Hsu, V., Uppati, S., McMichael, E., Duggan, M., Campbell, A., Keller, K., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1490 · Cited by 188

The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma

Ruella, M., Kenderian, S. S., Shestova, O. E., Fraietta, J. A., Qayyum, S., Zhang, Q., Maus, M. V., Liu, X., Nuñez-Cruz, S., Klichinsky, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1527 · Cited by 190

Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies

Ruella, M., Korell, F., Porazzi, P., & Maus, M. V. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00807-1 · Cited by 197

The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy

Landau, D. A., Sun, C., Rosebrock, D., Herman, S. E. M., Fein, J., Sivina, M., Underbayev, C., Liu, D., Hoellenriegel, J., Ravichandran, S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02329-y · Cited by 176

Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options

Kabacaoğlu, D., Ciecielski, K. J., Ruess, D. A., & Algül, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01878 · Cited by 181

Managing toxicities of Bruton tyrosine kinase inhibitors

Lipsky, A. H., & Lamanna, N. (2020) · Hematology · doi:10.1182/hematology.2020000118 · Cited by 174

Ibrutinib: First Global Approval

Cameron, F., & Sanford, M. (2014) · Drugs · doi:10.1007/s40265-014-0178-8 · Cited by 163

Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial

Bartlett, N. L., Costello, B. A., LaPlant, B. R., Ansell, S. M., Kuruvilla, J. G., Reeder, C. B., Thye, L. S., Anderson, D. M., Krysiak, K., Ramirez, C. A., et al. (2017) · Blood · doi:10.1182/blood-2017-09-804641 · Cited by 161

The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia

Herman, S. E. M., Montraveta, A., Niemann, C. U., Mora-Jensen, H. I., Gulrajani, M., Krantz, F., Mantel, R., Smith, L. L., McClanahan, F., Harrington, B. K., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0463 · Cited by 156

PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies

Jin, M., Fang, J., Peng, J., Wang, X., Xing, P., Jia, K., Hu, J., Wang, D., Ding, Y., Wang, X., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02176-8 · Cited by 162

Mantle cell lymphoma in 2022—A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments

Jain, P., & Wang, M. L. (2022) · American Journal of Hematology · doi:10.1002/ajh.26523 · Cited by 156

Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells

Patel, V. M., Balakrishnan, K., Бибикова, Е., Ayres, M., Keating, M. J., Wierda, W. G., & Gandhi, V. V. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1446 · Cited by 154

Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy

Roit, F. D., Engelberts, P. J., Taylor, R. P., Breij, E. C. W., Gritti, G., Rambaldi, A., Introna, M., Parren, P. W. H. I., Beurskens, F. J. M., & Golay, J. (2014) · Haematologica · doi:10.3324/haematol.2014.107011 · Cited by 152

Small Molecules Drive Big Improvements in Immuno‐Oncology Therapies

Huck, B. R., Kötzner, L., & Urbahns, K. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201707816 · Cited by 154

Biologically Driven Synthesis of Pyrazolo[3,4-d]pyrimidines As Protein Kinase Inhibitors: An Old Scaffold As a New Tool for Medicinal Chemistry and Chemical Biology Studies

Schenone, S., Radi, M., Musumeci, F., Brullo, C., & Botta, M. (2014) · Chemical Reviews · doi:10.1021/cr400270z · Cited by 148

How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia

Stephens, D. M., & Byrd, J. C. (2019) · Blood · doi:10.1182/blood-2018-11-846808 · Cited by 148

Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia

McWilliams, E. M., Mele, J. M., Cheney, C. M., Timmerman, E. A., Fiazuddin, F., Strattan, E., Mo, X. M., Byrd, J. C., Muthusamy, N., & Awan, F. T. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1226720 · Cited by 144

Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models

Haselmayer, P., Camps, M., Liu‐Bujalski, L., Nguyen, N. T. K., Morandi, F., Head, J. C., O’Mahony, A., Zimmerli, S. C., Bruns, L., Bender, A. T., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800583 · Cited by 143

The role of Bruton’s tyrosine kinase in autoimmunity and implications for therapy

Crofford, L. J., Nyhoff, L. E., Sheehan, J. H., & Kendall, P. L. (2016) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2016.1152888 · Cited by 142

Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies

Tillman, B. F., Pauff, J. M., Satyanarayana, G., Talbott, M., & Warner, J. L. (2017) · European Journal Of Haematology · doi:10.1111/ejh.13020 · Cited by 138

BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor

Özer, H. G., El‐Gamal, D., Powell, B., Hing, Z. A., Blachly, J. S., Harrington, B. K., Mitchell, S. R., Grieselhuber, N. R., Williams, K., Lai, T.-H., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0902 · Cited by 136

Targeted therapies in CLL: mechanisms of resistance and strategies for management

Woyach, J. A., & Johnson, A. J. (2015) · Blood · doi:10.1182/blood-2015-03-585075 · Cited by 134

Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia

Gill, S. I., Vides, V., Frey, N. V., Hexner, E. O., Metzger, S. T., O'Brien, M., Hwang, W., Brogdon, J. L., Suhoski, M. M., Fraietta, J. A., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007317 · Cited by 135

The Next Generation of Immunotherapy for Cancer: Small Molecules Could Make Big Waves

Kerr, W. G., & Chisholm, J. D. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800991 · Cited by 131

Targets for Ibrutinib Beyond B Cell Malignancies

Berglöf, A., Hamasy, A., Meinke, S., Palma, M., Krstic, A., Månsson, R., Kimby, E. K., Österborg, A., & Smith, C. I. E. (2015) · Scandinavian Journal of Immunology · doi:10.1111/sji.12333 · Cited by 132

Treatment resistance in diffuse large B-cell lymphoma

He, M. Y., & Kridel, R. (2021) · Leukemia · doi:10.1038/s41375-021-01285-3 · Cited by 134

Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms

Ruella, M., Kenderian, S. S., Shestova, O. E., Klichinsky, M., Melenhorst, J. J., Wasik, M. A., Lacey, S. F., June, C. H., & Gill, S. I. (2016) · Leukemia · doi:10.1038/leu.2016.262 · Cited by 132

T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease?

Roessner, P. M., & Seiffert, M. (2020) · Leukemia · doi:10.1038/s41375-020-0873-2 · Cited by 131

T Cell Subsets in Graft Versus Host Disease and Graft Versus Tumor

Jiang, H., Fu, D., Bidgoli, A., & Paczesny, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.761448 · Cited by 136

Bruton’s tyrosine kinase (BTK) as a promising target in solid tumors

Molina‐Cerrillo, J., Alonso‐Gordoa, T., Gajate, P., & Grande, E. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.06.001 · Cited by 130

Tumor microenvironment (TME)-driven immune suppression in B cell malignancy

Nicholas, N. S., Apollonio, B., & Ramsay, A. G. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.11.003 · Cited by 131

Targeting BTK in CLL: Beyond Ibrutinib

Bond, D. A., & Woyach, J. A. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00512-0 · Cited by 124

Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Saad, A. A., Lima, M. J. G. D., Anand, S. M., Bhatt, V. R., Bookout, R., Chen, G. L., Couriel, D. R., Stasi, A. D., El-Jawahri, A. R., Giralt, S., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0021 · Cited by 126

Bruton's Tyrosine Kinase: From X-Linked Agammaglobulinemia Toward Targeted Therapy for B-Cell Malignancies

Ponader, S., & Burger, J. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.1046 · Cited by 126

Immune checkpoint inhibitor combinations: Current efforts and important aspects for success

Kon, E., & Benhar, I. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.07.004 · Cited by 121

Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway

Kondo, K., Shaim, H., Thompson, P. A., Burger, J. A., Keating, M. J., Estrov, Z. E., Harris, D., Kim, E., Ferrajoli, A., Daher, M., et al. (2017) · Leukemia · doi:10.1038/leu.2017.304 · Cited by 124

Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study

Waller, E. K., Miklos, D. B., Cutler, C. S., Arora, M., Jagasia, M., Pusic, I., Flowers, M. E. D., Logan, A. C., Nakamura, R., Chang, S., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.06.023 · Cited by 119

Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study

Tempero, M. A., Oh, D., Tabernero, J. M., Reni, M., Cutsem, E. V., Hendifar, A. E., Waldschmidt, D., Starling, N., Bachet, J., Chang, H. M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.01.070 · Cited by 122

Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness

Barnestein, R., Galland, L., Kalfeist, L., Ghiringhelli, F., Ladoire, S., & Limagne, E. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2120676 · Cited by 118

Entering the Era of Targeted Therapy for Chronic Lymphocytic Leukemia: Impact on the Practicing Clinician

Byrd, J. C., Jones, J. J., Woyach, J. A., Johnson, A. J., & Flynn, J. M. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.8262 · Cited by 117

Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia

Yin, Q., Sivina, M., Robins, H. S., Yusko, E. C., Vignali, M., O'Brien, S. M., Keating, M. J., Ferrajoli, A., Estrov, Z. E., Jain, N., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601190 · Cited by 116

How I treat CLL patients with ibrutinib

Brown, J. R. (2017) · Blood · doi:10.1182/blood-2017-08-764712 · Cited by 114

Role of the tumor microenvironment in mature B-cell lymphoid malignancies

Fowler, N. H., Cheah, C. Y., Gascoyne, R. D., Gribben, J. G., Neelapu, S. S., Ghia, P., Bollard, C. M., Ansell, S., Curran, M. A., Wilson, W. H., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.139493 · Cited by 118

Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation

McDonald-Hyman, C. S., Turka, L. A., & Blazar, B. R. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa6853 · Cited by 113

Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment

de Weerdt, I., Hofland, T., de Boer, R., Dobber, J. A., Dubois, J., van Nieuwenhuize, D., Mobasher, M., de Boer, F., Hoogendoorn, M., Velders, G. A., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000360 · Cited by 110

A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era

Robinson, H. R., Qi, J., Cook, E. M., Nichols, C., Dadashian, E. L., Underbayev, C., Herman, S. E. M., Saba, N. S., Keyvanfar, K., Sun, C., et al. (2018) · Blood · doi:10.1182/blood-2018-02-830992 · Cited by 108

Interleukin-2-Inducible T-Cell Kinase (ITK) Deficiency - Clinical and Molecular Aspects

Ghosh, S., Bienemann, K., Boztuǧ, K., & Borkhardt, A. (2014) · Journal of Clinical Immunology · doi:10.1007/s10875-014-0110-8 · Cited by 107

Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia

Fiorcari, S., Maffei, R., Audrito, V., Martinelli, S., ten Hacken, E., Zucchini, P., Grisendi, G., Potenza, L., Luppi, M., Burger, J. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11782 · Cited by 107

Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study

Gopal, A. K., Schuster, S. J., Fowler, N. H., Trotman, J., Heß, G., Hou, J., Yacoub, A., Lill, M., Martin, P., Vitolo, U., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.8853 · Cited by 105

How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD

Jaglowski, S. M., & Blazar, B. R. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018013060 · Cited by 105

Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non‐Hodgkin lymphoma

Nakhoda, S., Vistarop, A., & Wang, Y. L. (2023) · British Journal of Haematology · doi:10.1111/bjh.18418 · Cited by 104

A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia

Chen, L. S., Bose, P., Cruz, N. D., Jiang, Y., Wu, Q., Thompson, P. A., Feng, S., Kroll, M. H., Qiao, W., Huang, X., et al. (2018) · Blood · doi:10.1182/blood-2018-06-860593 · Cited by 105

CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences

Vitale, C., & Strati, P. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00849 · Cited by 103

Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice

Schutt, S. D., Fu, J., Nguyen, H. D., Bastian, D. A., Heinrichs, J. L., Wu, Y., Liu, C., McDonald, D. G., Pidala, J., & Yu, X. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137641 · Cited by 101

Bruton’s Tyrosine Kinase (BTK) Inhibitors in Clinical Trials

Burger, J. A. (2013) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-013-0188-8 · Cited by 103

Regulation of B cell fate by chronic activity of the IgE B cell receptor

Yang, Z., Robinson, M. J., Chen, X., Smith, G. A., Taunton, J., Liu, W., & Allen, C. D. C. (2016) · eLife · doi:10.7554/elife.21238 · Cited by 100

Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia

Rogers, K. A., Ruppert, A. S., Bingman, A. K., Andritsos, L. A., Awan, F. T., Blum, K. A., Flynn, J. M., Jaglowski, S. M., Lozanski, G., Maddocks, K. J., et al. (2015) · Leukemia · doi:10.1038/leu.2015.273 · Cited by 100

B-cell receptor–mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma

Li, L., Zhang, J., Chen, J., Xu-Monette, Z. Y., Miao, Y., Xiao, M., Young, K. H., Wang, S., Medeiros, L. J., Wang, M. L., et al. (2018) · Blood · doi:10.1182/blood-2018-03-841015 · Cited by 97

Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects

Makaremi, S., Asadzadeh, Z., Hemmat, N., Baghbanzadeh, A., Sgambato, A., Ghorbaninezhad, F., Safarpour, H., Argentiero, A., Brunetti, O., Bernardini, R., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9091075 · Cited by 99

Ibrutinib: A Review in Chronic Lymphocytic Leukaemia

Deeks, E. D. (2017) · Drugs · doi:10.1007/s40265-017-0695-3 · Cited by 96

Combination Strategies to Augment Immune Check Point Inhibitors Efficacy - Implications for Translational Research

Varayathu, H., Sarathy, V., Thomas, B. E., Mufti, S. S., & Naik, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.559161 · Cited by 96

Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth

Chen, J., Kinoshita, T., Sukbuntherng, J., Chang, B. Y., & Elias, L. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0923 · Cited by 93

Abstract 492: Ibrutinib inhibits Interleukin-2 inducible kinase, driving a Th1 selective pressure in human leukemia patients that serves to alleviate tumor-induced immunosupression.

Dubovsky, J. A., Beckwith, K. A., Natarajan, G. K., Woyach, J. A., Jaglowski, S. M., Hessler, J. D., Liu, T.-M., Chang, B. Y., Larkin, K. T. M., Stefanovski, M. R., et al. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-492

Title: Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1 selective pressure in T-lymphocytes Short Title: Ibrutinib is an immunomodulatory ITK inhibitor

Dubovsky, J. A., Beckwith, K. A., Natarajan, G. K., Jaglowski, S. M., Zhong, Y., Hessler, J. D., Liu, T.-M., Chang, B. Y., Larkin, K. M., Stefanovski, M. R., et al. (2016)

Ibrutinib Also Inhibits ITK

(2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-rw2013-168

Two targets for the price of one

Ansell, S. M. (2013) · Blood · doi:10.1182/blood-2013-08-518548 · Cited by 8

Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells

Dubovsky, J. A., Beckwith, K. A., Woyach, J. A., Jaglowski, S. M., Hessler, J. D., Chang, B. Y., Larkin, K. T. M., Stefanovski, M. R., Frissora, F. W., Smith, L. L., et al. (2012) · Blood · doi:10.1182/blood.v120.21.775.775 · Cited by 3